■部分水解配方(pHF)作为营养干预措施的一部分,以防止过敏表现(AM)的发展的作用受到质疑,和每个特定的pHF的功效应得到证实。
目的研究基于乳清的pHF对过敏高危婴儿头6个月内发生牛乳蛋白过敏(CMPA)和特应性皮炎(AD)的风险降低作用。
■在多中心双盲随机对照环境中,健康的非完全母乳喂养的足月婴儿,接受特定的基于乳清的pHF或基于标准牛乳的配方(SF),并在2、4和6个月大时对AM进行临床评估,由客观评分工具SCORAD和CoMiSS支持。CMPA通过开放式食物挑战得到证实。进行意向治疗(ITT)和按方案(PP)分析。
■331名随机受试者(ITT分析集),160接收pHF和171接收SF。pHF组中有6名(3.8%)婴儿和SF组中有12名(7%)婴儿发生了CMPA(p=0.186)。与SF相比,接受pHF的患者的AD发生率显着降低(10.6%vs.18.7%,p=0.024),具有相对风险(RR,95%CI)为0.54(0.32,0.92),特别是在调整AD家族史时[6.5%与27.3%,RR0.24(0.07,0.78),p=0.018]代表风险降低76%。PP分析显示类似的结果。
■这种特定的基于乳清的pHF降低了AD发展的风险,特别是那些有AD家族史的人,并且倾向于减少过敏高风险的非纯母乳喂养婴儿的CMPA的发展。A.R.T.研究表明,这种特殊的pHF可能有助于预防过敏表现的措施。然而,需要进一步的研究来证实这种降低风险的效果.
UNASSIGNED: The role of partially hydrolyzed formulas (pHF) as part of nutritional interventions to prevent the development of allergic manifestations (AM) is questioned, and efficacy of each specific pHF should be substantiated.
UNASSIGNED: To investigate the risk-reduction effect of a whey-based pHF on the development of cow\'s milk protein allergy (CMPA) and atopic dermatitis (AD) in infants at high-risk for allergy within the first 6 months of life.
UNASSIGNED: In a multicenter double-blinded randomized controlled setting, healthy non-exclusively breastfed full-term infants, received either a specific whey-based pHF or a standard cow\'s milk-based formula (SF) and were clinically assessed for AM at 2, 4, and 6 months of age, supported by the objective scoring tools SCORAD and CoMiSS. CMPA was confirmed by open food challenge. Intention-to-Treat (ITT) and Per-Protocol (PP) analyses were performed.
UNASSIGNED: Of 331 randomized subjects (ITT analysis set), 160 received the pHF and 171 the SF. Six (3.8%) infants in the pHF and 12 (7%) in the SF group developed CMPA (p = 0.186). AD incidence was significantly lower in those receiving pHF as compared to SF (10.6% vs. 18.7%, p = 0.024) with a relative risk (RR, 95% CI) of 0.54 (0.32, 0.92), in particular when adjusting for family history of AD [6.5% vs. 27.3%, RR 0.24 (0.07, 0.78), p = 0.018] representing a risk reduction of 76%. The PP analysis showed similar results.
UNASSIGNED: This specific whey-based pHF reduced the risk of AD development, particularly in those with a family history of AD, and tended to reduce the development of CMPA in non-exclusively breastfed infants at high-risk for allergy. The A.R.T.
study suggests that this particular pHF may contribute to measures aimed at prevention of allergic manifestations. However, further studies are needed to confirm this risk-reduction effect.